Clinical trials: Advanced/Recurrent Ovarian Cancer
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced or Metastatic Solid Tumors, Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Trial name
- NCT06257758
- Testing
- VIO-01
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Valerio Therapeutics
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
This clinical trial evaluates the effects a probiotic intervention has on the gut and vaginal microbiome in patients undergoing chemotherapy for ovarian cancer that may have spread from where it first started to nearby tissue…
- Conditions
- Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8
- Trial name
- NCT07144826
- Testing
- Biospecimen Collection, Probiotic, Questionnaire Administration
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Platinum-resistant Ovarian Cancer (PROC)
Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
This project plans to conduct a prospective, multicenter clinical study. The intended participants are patients with histologically confirmed advanced (FIGO III/IV stage) ovarian serous carcinoma, ovarian endometrioid carcinoma…
- Trial name
- RIFOC003 (NCT07075250)
- Testing
- Realgar-Indigo Naturalis Formulation Combined with Anlotinib
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- NCT01233505
- Testing
- veliparib, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer
Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer
Randomized clinical trial to asses the efficacy of closed abdomen hyperthermia intraperitoneal chemotherapy with paclitaxel in ovarian cancer.
- Trial name
- hipecova (NCT02681432)
- Testing
- HIPEC, No HIPEC
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- PEDRO VILLAREJO CAMPOS
Renal Cell Carcinoma, Urothelial Carcinoma
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent
- Trial name
- NCT03827837
- Testing
- SHR-1210, Famitinib
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer, Advanced Malignant Solid Tumor
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
- Trial name
- NCT07389239
- Testing
- Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Female Reproductive Cancer
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary…
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00182767
- Testing
- ixabepilone, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Endometrial Cancer
Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00118300
- Testing
- capecitabine, brachytherapy, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ovarian Cancer (OvCa), Recurrent Ovarian Cancer
Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer
The goal of this clinical trial is to investigate if CALM-TF (Trauma-Focused Managing Cancer and Living Meaningfully) is effective in treating traumatic stress symptoms in women with advanced ovarian cancer.
- Trial name
- CALM-TF (NCT07286162)
- Testing
- Trauma-Focused Managing Cancer and Living Meaningfully
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Male Breast Cancer, Recurrent Breast Cancer
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and mifepristone when given together with carboplatin in treating patients with breast cancer that is metastatic or cannot be removed by…
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT02046421
- Testing
- mifepristone, carboplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Chicago
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Ovarian Cancer, Fallopian Tube Cancer
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Preclinical and early-phase clinical data suggest that immune modulation represents a treatment strategy that is worthy of further investigation in relapsed epithelial ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Extra Renal Origin
- Trial name
- NCT03355976
- Testing
- Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Brown University